AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine
The submission is based on two pivotal Phase 3 studies evaluating atogepant in adult patients with episodic and chronic migraine If approved, atogepant would be the first daily oral calcitonin… Read More




